- Nineteen abstracts underscore AbbVie's continued pursuit of research on behalf of patients living with chronic dermatologic conditions
- Majority of abstracts evaluate risankizumab efficacy and safety in moderate to severe plaque psoriasis, with additional presentations of upadacitinib in atopic dermatitis and HUMIRA® (adalimumab) in psoriatic disease
- First integrated efficacy analyses from two risankizumab pivotal studies will highlight response over time and across various patient subgroups
PR Newswire
NORTH CHICAGO, Ill., Feb. 25, 2019